Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways Disease
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Berodual® Respimat® solution for inhalation
- Registration Number
- NCT02231372
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
Tolerability, efficacy and handling of Berodual® Respimat® 20/50µg/dose solution for inhalation in patients with chronic obstructive airways disease in daily practice
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 4602
Inclusion Criteria
- Men and women presenting with symptoms of chronic obstructive pulmonary disease
- Both previously untreated patients and patients treated previously with Berodual® or with other anti-obstructive respiratory tract agents may be included
Exclusion Criteria
- Patients presenting with the general and specific contraindications listed in the Patient Information Leaflet and the Basic Product Information
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description chronic obstructive airways disease patients Berodual® Respimat® solution for inhalation -
- Primary Outcome Measures
Name Time Method Global assessment of efficacy by the patients rated on 5-point scale after 4 weeks Number of awakening due to nocturnal breathlessness rated on 4-point scale up to 4 weeks Change in restriction of activity due to breathlessness rated on a 4-point scale up to 4 weeks Change in overall severity rated on 3-point scale up to 4 weeks Change in reduction in breathlessness rated on a 4-point scale up to 4 weeks Number of patients with adverse drug reactions up to 4 weeks Global assessment of efficacy by the investigator rated on 5-point scale after 4 weeks
- Secondary Outcome Measures
Name Time Method